Dr. Nitin Jain

Nitin Jain, M.D., is an Assistant Professor in the Department of Leukemia at MD Anderson Cancer Center in Houston, Texas, USA. He earned his medical degree from All India Institute of Medical Sciences, New Delhi in 2002. He then moved to the United States and completed his internal medicine residency training at the Medical College of Wisconsin, Milwaukee. He then completed a year of clinical fellowship in leukemia at MD Anderson Cancer Center followed by another year of leukemia research fellowship at the Memorial Sloan-Kettering Cancer Center in New York. He then pursued hematology/oncology fellowship from the University of Chicago. After completed his medical training, he was recruited as a faculty member in the Department of Leukemia at MD Anderson in 2012. Dr. Jain clinical interests focus on new drug development for patients with leukemia, especially chronic lymphocytic leukemia (CLL) and acute lymphoblastic leukemia (ALL).

Dr. Jain is PI of several investigated-initiated phase I-II clinical trials, including checkpoint inhibitors in CLL, combination targeted therapies (ibrutinib and venetoclax) in CLL, and a trial with JAK2 inhibitor in Ph-like ALL. He has published papers in prominent journals including Journal of Clinical Oncology, Blood, Clinical Cancer Research, Cancer, Leukemia Lymphoma, Leukemia Research and others. He has won many awards during his career including Sardari Lal Kalra Gold Medal in Microbiology and Merit Award from the American Society of Clinical Oncology (ASCO). He also received High-Impact Clinical Research Support Award from MD Anderson Cancer Center in the year 2014 and 2016.